Six months fixed duration multidrug therapy in paucibacillary leprosy: risk of relapse and disability in Agra PB cohort study
Open Access
- 19 July 2012
- Vol. 2 (4), e001403
- https://doi.org/10.1136/bmjopen-2012-001403
Abstract
Background Many studies have focused on multidrug therapy (MDT) for multibacillary (MB) leprosy and rarely on long-term outcome of paucibacillary (PB) leprosy having recommendation of therapy for 6 months fixed duration therapy for PB patients. Studies on measuring risk of disability are rare. The present study is to assess the cure; default, relapse and disability in a prospective cohort of PB leprosy during follow-up of >4 years after treatment. Design Prospective. Setting Primary in our field area of Agra District. Participants 920 PB leprosy patients entered the study, 621 completed treatment, 599 followed finally including 271 males, no ethnic differentiation, patients of all age groups except for children below 5 years and old persons above 70 years were not included. Treatment 6 months fixed duration MDT as recommended by WHO. Primary and secondary outcomes Treatment completion, cure, relapse and development of disability based on clinical assessment by well-experienced doctors. Statistical methods Data have been analysed using SPSS software, risk is computed as incidence per 100 person–years (PY) and test of significance used. Results Study reports 91% cure rate. Incidence of relapse was 1.3/100 PY with no significant variation by age, sex, delay in detection, patches and nerves. Crude incidence of disability was 2.2% and varied significantly by age and nerve thickening but not by sex, number of patches, nerves and delay in treatment. Incidence of disability was 0.50/100 PY in treatment completed and 0.43 among defaulters. Conclusion The study concludes that relapses do occur after MDT treatment but at the level of 1–2%, incidence of disability remains low (<1/100 PY) in PB leprosy. Low incidence of relapse and disability suggests that 6 months therapy is quite effective. However, further improvement may help to improve its efficacy. Longer follow-up may add to efficacy measures.This publication has 14 references indexed in Scilit:
- Risk of developing disability in pre and post-multidrug therapy treatment among multibacillary leprosy: Agra MB Cohort studyBMJ Open, 2012
- Leprosy scenario in Agra: epidemiological observations from rapid population survey 2004-06.2008
- A study on trend of relapse in leprosy and factors influencing relapse.2005
- Epidemiology of leprosy in urban AgraLeprosy Review, 2003
- An analysis of relapsed leprosy cases.2000
- Risk of relapse in leprosy. The Leprosy Unit, WHO.1995
- Relapses among leprosy patients treated with multidrug therapy: experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia; practical difficulties with diagnosing relapses; operational procedures and criteria for diagnosing relapses.1992
- Treatment failures with multidrug therapyLeprosy Review, 1992
- Relapse or reversal reaction: the case for a therapeutic trial of steroids.1988
- A study of relapse in non lepromatous and intermediate groups of leprosy.1985